Investing in Pipeline Drug Companies

AbbVie --AbbVie is tackling diseases where there is a significant patient need for more and better solutions, with a focus on hepatitis C, immune-mediated conditions, cancer and more. See AbbVie's Pipeline.

Abbott Labs -Learn more about our groundbreaking products designed to help people stay strong and healthy in all stages of life. Product Pipeline

Amgen --A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness. Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects. Human genetic validation is used whenever possible to enhance the likelihood of success. See Amgen's Pipeline

Annexon -- Develops disease-modifying therapeutics for patients suffering from neurological disorders such as Huntington’s disease and Alzheimer’s disease by targeting complement-mediated neurodegeneration (CMND). See Pipeline.

ARIAD Pharmaceuticals --Their pipeline centers on promising internally developed compounds. Each was discovered by their own people. Each targets proven pathways to disrupting cancer growth. Each has potential for important patient impact. See ARIAD'S Pipeline.

AstraZeneca -- AstraZeneca's pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. Cardiovascular and Metabolic diseases, Oncology, Respiratory, Inflammation and Autoimmunity, Infection and Neuroscience and Gastrointestinal See AstraZeneca's Pipeline.

Bavarian Nordic--Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. See Pipeline for Bavarian Nordic.

Bristol-Myers Squibb-- A BioPharma leader focused on helping to address the unmet medical needs of patients with serious diseases. In 2015, they invested $4.04 billion in R&D, which included the discovery and development of new medicines for patients including: cardiovascular, fibrotic disease, genetically defined diseases, and immune-oncology,. See Pipeline for Bristol-Myers Squibb.

Celgene --Leading-edge scientific research in oncology remains our passion. We are focused on developing disruptive approaches to high value disease pathways that translate into life-enhancing medicines with the ultimate goal to change the course of human health while promising to always put patients first. From Receptos aquisition --ozanimod, an S1P1 receptor agonist. Ozanimod is currently being studied in three indications: relapsing multiple sclerosis (RMS), ulcerative colitis, and Crohn's disease.

See Celgene Pipeline

Daiichi-Sankyo--develop and expand a robust pipeline to address patients' unmet medical needs. See Pipeline Chart for Daiichi-Sanyo.

Eli Lilly and Company--Lilly currently has the richest mid-to-late stage pipelinglaxe in their history, representing a variety of therapeutic areas including cancer, diabetes, neuroscience and autoimmunity. See the Pipeline for Lilly.

Exelixis Inc. --The Exelixis pipeline includes our lead compounds, cabozantinib and cobimetinib, as well as other programs that are the subject of partnerships and collaborations with other biopharmaceutical companies. See Pipeline for Exelis.

GlaxoSmithKline -Their medicines and vaccines in development are classified into three stages: phase I, phase II and phase III. These studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval. See Pipeline for GSK.

Janssen -of Johnson and Johnson-Developing treatments for patients in five important therapeutic areas of healthcare: cardiovascular and metabolism, immunology, infectious diseases, neuroscience and oncology. See Pipeline for Janssen.

Juno Therapeutics--Juno’s pipeline of therapeutic T cell product candidates apply our CAR and TCR technologies against a variety of cancer targets.See the Pipeline for Juno

Genentech--R&D activities are focused on applying excellent science to discover and develop potential new medicines with the goal of becoming first-in-class or best-in-class. See Pipeline for Genentech.

Inovio --Inovio research and development is focused on applying excellent science to discover and develop potential new synthetic DNA immunotherapies with the goal of creating first-in-class or best-in-class therapeutics and/or preventives. Currently testing a Zika vaccine. See pipeline

M3 Biotechnology --M3 Biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. The lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. See M3 Website.

MedImmune--With more than 120 biologics in R&D and 40 products in clinical development, MedImmune have one of the strongest, most robust pipelines in the industry. See the Pipeline for MedImmune.

Medrontics -As a global leader in medical technology, services, and solutions, Medronics is collaborating with others to take on the industry's greatest challenges. See Pipeline

Merck --strives to identify the most critical needs of consumers and customers, and through continuous innovation they challenge themselves to meet those needs. - See the pipeline for Merck.

Novartis--Novartis is consistently rated as having one of the industry’s most respected development pipelines, with more than 200 projects in clinical development.mMany of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. See Novartis Pipeline.

Neurophage --Neurophage’s breakthrough GAIM platform generates therapeutics for the treatment of neurodegenerative diseases and many rare peripheral amyloidoses, all diseases characterized by the accumulation of misfolded proteins. see Neurophage Pipeline.

OncoMed--OncoMed Pharmaceuticals is a focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting cancer stem cells. OncoMed was founded with a focus on cancer stem cells, which are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. Also known as tumor-initiating cells, cancer stem cells are characterized by the ability to to divide and give rise to new cancer stem cells (self-renewal) and to change into the other cells that form the bulk of the tumor (differentiation). Lead product is Demcizumab. See Pipeline for OncoMed

Össur -- state-of-the-art bionic technology combines mechanics and electronics to effectively mimic the amputee’s natural sensory and motor control functions. This advanced technology helps to reproduce accurately certain functions that have been lost due to amputation. See Pipeline

Pfizer--Pfizer is prioritizing its research and development efforts in areas with the greatest scientific and commercial promise: immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain, and vaccines. Through major research efforts across multiple modalities — including small molecules, biological vaccines. See the Pfizer Pipeline.

Pharmacyclics--BTK inhibitors (Brutons Tyrosine Kinase inhibitor) for cancer and autoimmune diseases. See the Pipeline. Note: Acquired by Abbvie.

Roche --Roche have more than 18,000 employees working on research and development to deliver medical innovations. See Pipeline for Roche.

Sanofi/RegeneronPharmaceutical --Regeneron has a long history of delivering breakthrough technologies and medicines, often aided by our history of highly successful collaborations with industry and academic partners. See Pipeline

Seattle Genetics --Seattle Genetics is the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Their robust pipeline of empowered antibody-based therapies is designed to address significant unmet medical needs. See the Pipeline.

Syndax Pharmaceuticals-- Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of combination therapies in multiple cancer indications. -- See the Pipeline.

Sunovion Pharmaceuticals Inc. -- Sunovion develops pharmaceutical products that improve the lives of millions of patients. Sunovion science at present specializes in two distinct therapeutic areas—respiratory conditions and disorders of the central nervous system. See Sunovion Pipeline.

Treventis Coroporation-Treventis Corporation pre clinical candidate TRV 101 demonstrates significant reduction in both amyloid beta and tau toxic aggregates in animal models of Alheimer's Disease. Read about Trenvtis.